Blow For Seagen As England Rejects Funding For Advanced Breast Cancer Drug Tukysa

England’s health technology assessment body said it would continue to work with Seagen to address the reasons why its newly published draft guidance has recommended against using Tukysa on the National Health Service.

Health technology assessment (HTA) body NICE has preliminarily recommended against the use of Seagen’s Tukysa (tucatinib), in combination with trastuzumab and capecitabine, as a third-line treatment for advanced breast cancer because it does not believe that the treatment is good value for money.

While NICE called Tukysa “a promising, innovative new treatment,” it said that the cost-effectiveness estimates for the combination product were...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from Pink Sheet